Painchek Granted European Patent For Pain Assessment Technology

PainChek Ltd (ASX: PCK) has been granted a patent in 20 European nations by the European Patent Office (EPO).

The patent application, entitled “A Pain Assessment Method and System”, enables PainChek to safeguard its intellectual property within Europe.

Pain management app

Using AI technology to support a modern pain assessment framework, PainChek will identify the presence of pain even when it’s not obvious.

It enables best practice pain management for people living with pain in any environment.

The PainChek app is available on smartphones and tablets.

Patent protection until 2035

The patent has been granted in Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

PainChek has secured patent protection for all these regions until 2035.

This patent further strengthens PainChek’s global intellectual property portfolio, which includes existing patents in the USA, Japan, and China.

“Pivotal achievement”

PainChek CEO Philip Daffas said: “The granting of this European patent is a pivotal achievement for PainChek as it solidifies our position in one of the world’s largest healthcare markets, including the UK which is a particularly important growth region for the company.

“This protection enhances our ability to deliver innovative pain assessment solutions to a broader audience, ensuring better pain assessment and management for individuals in need.”

PainChek had a cash balance of A$4.4 million as on 31 March 2024.



JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest